Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
शेयरों में रैंक #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
शेयर मूल्य
$263.25
मार्केट कैप
$465.10B
बदलाव (1 दिन)
-0.68%
बदलाव (1 वर्ष)
18.26%
देश
US
व्यापार AbbVie Inc. (ABBV)

श्रेणी

AbbVie Inc. (ABBV) के लिए EPS
June 2026 TTM तक का EPS: $3.55
AbbVie Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) $3.55 है। 2024 के अंत में, कंपनी का EPS $2.40 था, जो 2023 के EPS $2.73 के की तुलना में कमी था।
AbbVie Inc. के लिए 2009 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
वर्ष EPS परिवर्तन
2026 (TTM) $3.55 49.16%
2025 $2.38 -0.83%
2024 $2.40 -12.09%
2023 $2.73 -58.95%
2022 $6.65 2.62%
2021 $6.48 137.36%
2020 $2.73 -48.49%
2019 $5.30 43.63%
2018 $3.69 11.48%
2017 $3.31 -9.32%
2016 $3.65 15.87%
2015 $3.15 183.78%
2014 $1.11 -56.98%
2013 $2.58 -22.99%
2012 $3.35 58.02%
2011 $2.12 -18.15%
2010 $2.59 -9.76%
2009 $2.87 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
कंपनी EPS EPS अंतर देश
$29.89 741.97%
US
$8.65 143.66%
US
$20.39 474.34%
CH
$1.26 -64.51%
US
$7.19 102.54%
CH